{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-26-000405","form_type":"8-K/A","ticker":"BCRX","cik":"0000882796","company_name":"BIOCRYST PHARMACEUTICALS INC","filed_at":"2026-01-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:37.905144+00:00","generated_at":"2026-05-16T08:38:10.260855+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"BioCryst appoints Dr. Jill Milne to Compensation and Science Committees following Astria merger close","bullets":["Merger with Astria Therapeutics completed on January 23, 2026; Astria becomes wholly owned subsidiary.","Dr. Jill C. Milne appointed to BioCryst Board of Directors effective as of closing date.","On January 20, 2026, Board appointed Dr. Milne to Compensation and Science Committees."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-26-000405","json":"https://secwatch.observer/filing/0001171843-26-000405.json","markdown":"https://secwatch.observer/filing/0001171843-26-000405.md","text":"https://secwatch.observer/filing/0001171843-26-000405.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882796/000117184326000405/0001171843-26-000405-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882796/000117184326000405/f8ka_012226.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T08:38:10.260855+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}